Comprehensive Tumor Panel 526 Genes: Advanced Cancer Genomic Profiling
Understanding Comprehensive Cancer Genomic Testing
The Comprehensive Tumor Panel 526 Genes represents the forefront of precision oncology, providing an exhaustive analysis of cancer-related genetic alterations through next-generation sequencing technology. This advanced diagnostic tool examines 526 carefully selected genes known to play critical roles in cancer development, progression, and treatment response. By analyzing multiple genomic biomarkers simultaneously, this comprehensive panel offers clinicians unprecedented insights into the molecular drivers of individual cancers, enabling truly personalized treatment strategies.
What This Test Measures and Detects
Our comprehensive tumor panel provides detailed analysis across multiple genomic alteration types:
Single Nucleotide Variants (SNVs)
- Point mutations affecting single DNA nucleotides
- Critical for identifying targetable driver mutations
- Helps determine sensitivity to specific targeted therapies
Small Insertions and Deletions (Indels)
- Small DNA sequence insertions or deletions
- Can cause frameshift mutations affecting protein function
- Important for understanding tumor suppressor gene inactivation
Gene Fusions
- Chromosomal rearrangements creating fusion genes
- Often result in oncogenic fusion proteins
- Key biomarkers for targeted therapy selection
Tumor Mutational Burden (TMB)
- Quantifies total number of mutations per megabase
- Predicts response to immunotherapy
- Higher TMB often correlates with better immunotherapy outcomes
Microsatellite Instability (MSI)
- Measures DNA mismatch repair deficiency
- Strong predictor of immunotherapy response
- Important for Lynch syndrome screening
Who Should Consider This Comprehensive Cancer Panel
This advanced genomic test is particularly valuable for patients with:
Solid Tumor Cancers
- Advanced or metastatic cancers requiring treatment guidance
- Cancers with limited treatment options
- Patients seeking targeted therapy or immunotherapy options
- Cases where standard treatments have failed
Specific Clinical Scenarios
- Newly diagnosed advanced cancers
- Recurrent or progressive disease
- Cancers of unknown primary origin
- Patients with rare or uncommon tumor types
- Those considering clinical trial participation
Benefits of Comprehensive Genomic Profiling
Personalized Treatment Selection
By identifying specific genetic alterations, this test enables oncologists to select therapies that target the molecular drivers of your cancer, potentially improving treatment efficacy while reducing unnecessary side effects.
Immunotherapy Guidance
The TMB and MSI analysis provides critical information about your likelihood of responding to immune checkpoint inhibitors, helping to determine whether immunotherapy represents an appropriate treatment strategy.
Comprehensive Biomarker Analysis
Unlike single-gene tests, this panel evaluates multiple biomarkers simultaneously, providing a complete picture of your tumor’s genomic landscape and identifying all potential therapeutic targets in a single analysis.
Clinical Trial Matching
The comprehensive genetic profile can help identify eligibility for specific clinical trials based on your tumor’s unique molecular characteristics, potentially opening access to novel therapeutic approaches.
Understanding Your Test Results
Result Interpretation Framework
Your comprehensive genomic profiling report will include detailed information about:
- Actionable Mutations: Genetic alterations with approved targeted therapies
- Investigational Targets: Mutations that may qualify you for clinical trials
- Prognostic Markers: Genetic changes that provide information about disease course
- Resistance Mutations: Alterations that may indicate resistance to specific treatments
Clinical Actionability
Results are categorized based on clinical significance and therapeutic implications, with clear guidance on FDA-approved therapies, clinical trial options, and emerging treatment strategies relevant to your specific genomic profile.
Test Details and Pricing
| Test Component | Details |
|---|---|
| Test Name | Comprehensive Tumor Panel SNVs Small Indels Fusions TMB MSI 526 Genes |
| Discount Price | $1,976 USD |
| Regular Price | $3,000 USD |
| Turnaround Time | 4 weeks |
| Sample Type | FFPE Tissue Block |
| Testing Method | Next-Generation Sequencing (NGS) |
Nationwide Testing Availability
We have diagnostic centers conveniently located across the United States, serving patients in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, Austin, Jacksonville, Fort Worth, Columbus, San Francisco, and many other cities. Our network ensures accessible advanced cancer genomic testing for patients nationwide.
Take the Next Step in Your Cancer Journey
Don’t leave your treatment decisions to chance. Comprehensive genomic profiling can provide the critical information needed to develop the most effective, personalized treatment strategy for your specific cancer. Our team of oncology specialists and genetic counselors are ready to help you understand how this advanced testing can benefit your care.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your Comprehensive Tumor Panel testing and take control of your cancer treatment journey with precision medicine.
